Ads
related to: crispr therapeutics
Search results
CRISPR's (CRSP) Q1 Loss Narrower-Than-Expected, Sales Miss
Zacks via Yahoo Finance· 6 days agoCRISPR Therapeutics (CRSP) reports mixed earnings results for first-quarter 2024. Management claims...
CRISPR Therapeutics (NASDAQ:CRSP) Stock Price Down 2.1% After Analyst Downgrade
ETF DAILY NEWS· 4 days agoCRISPR Therapeutics AG (NASDAQ:CRSP – Get Free Report) shares dropped 2.1% during trading on Friday after Oppenheimer lowered their price target on the ...
Investors Heavily Search CRISPR Therapeutics AG (CRSP): Here is What You Need to Know
Zacks via Yahoo Finance· 2 days agoRecently, Zacks.com users have been paying close attention to CRISPR Therapeutics (CRSP). This makes...
CRISPR Therapeutics’ (CRSP) Neutral Rating Reiterated at Cantor Fitzgerald
ETF DAILY NEWS· 2 days agoCantor Fitzgerald reissued their neutral rating on shares of CRISPR Therapeutics (NASDAQ:CRSP – Free Report) in a research note issued to investors on Thursday ...
CRISPR Therapeutics AG (CRSP) Reports Q1 Loss, Misses Revenue Estimates
Zacks via Yahoo Finance· 7 days agoCRISPR Therapeutics (CRSP) delivered earnings and revenue surprises of 12.27% and 93.94%,...
Broker Revenue Forecasts For CRISPR Therapeutics AG (NASDAQ:CRSP) Are Surging Higher
Simply Wall St. via Yahoo Finance· 4 days agoCRISPR Therapeutics AG (NASDAQ:CRSP) shareholders will have a reason to smile today, with the...
CRISPR Therapeutics AG Reports Q1 2024 Earnings: Misses Analyst Net Income Forecast
GuruFocus.com via Yahoo Finance· 5 days agoCollaboration Expense: Rose to $47.0 million, compared to $42.2 million in the first quarter of 2023. On May 8, 2024, CRISPR Therapeutics AG (NASDAQ:CRSP ...
We're Interested To See How CRISPR Therapeutics (NASDAQ:CRSP) Uses Its Cash Hoard To Grow
Simply Wall St. via Yahoo Finance· 5 days agoNonetheless, only a fool would ignore the risk that a loss making company burns through its cash too...
2 Healthcare Stocks to Buy and Hold for Great Long-Term Potential
Motley Fool via Yahoo Finance· 19 hours agoOver the long term, the cheap valuation ratios mean that it's priced to appreciate if the company...
Vertex Pharmaceuticals Is Racing Towards a New Blockbuster: Why the Stock Is a Smart Buy
The Motley Fool via AOL· 3 days agoThe biotech is now expanding its areas of focus. It recently earned approval for Casgevy, a...
